MindMed
phase study results key phase study results support progression of into planned upcoming phase clinical program well tolerated up to per day in single ascending dose sad and per day in the multiple ascending dose mad linear maintained across the tested doses and frequencies clinical effects align with potent engagement regimen aligns with preclinical evidence offers potential to be a more effective regimen in withdrawal | MindMed
Company
Deck Type
Deck date
May 2022
Slide
33 of 40
Similar slides by MindMed
Investor Presentation
June 2023
Related slides by other companies
Results
May 2023
Investor Presentation
March 2023
Investor Conference
April 2023
Investor Presentation
August 2023
Other recent decks by MindMed
Results
November 2023
Investor Presentation
September 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io